Clinical Trial Updates: CIDP Interim Analysis, Setmelanotide Phase 3 Results & Verekitug Trial Data

Clinical research continues to advance across neurology, metabolic disorders, and inflammatory diseases. Recent updates highlight interim Phase 3 analysis plans in chronic inflammatory demyelinating polyneuropathy (CIDP), positive Phase 3 results for a rare obesity therapy, and encouraging data from a trial targeting chronic nasal polyps. These developments illustrate how innovative therapies are progressing through different stages of clinical evaluation.

Recent reports featured by Clinical Trial Vanguard provide insight into these important milestones.

Dianthus to Discuss Interim Phase 3 CIDP Trial Results

Dianthus Therapeutics has indicated that it will discuss interim findings from its Phase 3 CAPTIVATE trial in patients with CIDP. Interim analyses in such studies often evaluate responder rates and help determine the optimal design for later phases of the program. In CIDP research—where disease variability and background therapies can affect outcomes—this early look at data can help refine enrollment criteria and strengthen statistical assumptions for the remaining trial phases.

More details are available in Dianthus to Discuss Interim Phase 3 CIDP Trial Results.

Rhythm Pharma Reports Positive Phase 3 Setmelanotide Trial Data

Rhythm Pharmaceuticals has reported encouraging outcomes from the Phase 3 TRANSCEND trial evaluating setmelanotide for patients with hypothalamic obesity. In the expanded dataset, the therapy achieved an 18.8% placebo-adjusted difference in BMI reduction at 52 weeks, while hunger scores also improved significantly compared with placebo.

The new dataset has been submitted to the FDA as part of a supplemental application seeking label expansion for the therapy.

Learn more in Rhythm Pharma Sees Positive Phase 3 Setmelanotide Trial Data.

New VIBRANT Trial Data on Verekitug for Chronic Nasal Polyps

Advancements are also emerging in respiratory and inflammatory diseases. New analyses from the Phase 2 VIBRANT trial evaluating verekitug in patients with chronic rhinosinusitis with nasal polyps showed significant improvements in both nasal polyp scores and congestion symptoms. The study reported placebo-adjusted reductions in polyp score and improvements in congestion, along with a 76% reduction in surgery or systemic steroid interventions compared with placebo.

These findings may support further development of verekitug in both nasal polyps and related inflammatory conditions.

Further information can be found in New VIBRANT Trial Data on Verekitug for Chronic Nasal Polyps.

Key Trends Across Emerging Clinical Research

These developments highlight several important trends shaping the clinical trial ecosystem:

• Increasing use of interim analyses to optimize late-stage trials
• Continued development of targeted therapies for rare metabolic disorders
• Expansion of biologic treatments for chronic inflammatory diseases

Tracking such updates helps researchers, clinicians, and industry stakeholders stay informed about evolving clinical strategies and therapeutic innovation.